LUCID CAPITAL MARKETS Initiates Coverage On Insight Molecular with Buy Rating, Announces Price Target of $8
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Insight Molecular (NASDAQ:IMDX) with a Buy rating and announces Price Target of $8.
LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Insight Molecular (NASDAQ:IMDX) with a Buy rating and announces Price Target of $8.